Biotage resolves upon a rights issue

On September 12, 2005 the board of Biotage AB resolved, based on the authorization to the board by the extraordinary shareholders’ meeting held on August 30, 2005, to increase the company’s share capital by not more than SEK 8,044,212 through an issue of not more than 8,044,212 new ordinary shares, or such higher amount or such higher number of shares that may come from exercise of warrants entitling to subscription of shares. The issue is to be executed with preferential rights for the shareholders. The record day for receiving subscription rights shall be October 31, 2005. Each existing share shall entitle to 1 subscription right. 10 subscription rights shall entitle to subscription of 1 new share. Subscription of shares shall be made from November 3, 2005 and until November 23, 2005. Subscription of shares through preferential rights shall be made by payment of an issue price of SEK 6 per share. The new issue increases the share capital to, in aggregate, not more than SEK 88,486,320 (provided that no exercise of warrants is executed prior to September 30, 2005). In order for warrant holders to have the right to participate in the share issue with shares issued through exercise of warrants, such exercise must have been executed no later than September 30, 2005. The rights issue is executed to refinance the remaining debt financing regarding the acquisition of Argonaut’s business. Contact: Jeff Bork, President and CEO Tel: +46 734 22 16 60, jeff.bork@biotage.se